Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol
I. Hann et al., Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol, BR J HAEM, 113(1), 2001, pp. 103-114
The single most important prognostic determinant in childhood acute lymphob
lastic leukaemia (ALL) is effective therapy and changes in therapy may infl
uence the significance of other risk factors, The effect of intensified the
rapy on the importance of currently recognized phenotypic and genotypic det
erminants of outcome was assessed in 2090 children enrolled on the Medical
Research Council United Kingdom acute lymphoblastic leukaemia XI (MRC UKALL
XI) protocol. Treatment allocation was not determined by risk factors. Mul
tivariate analysis confirmed the dominant influence on prognosis of age, se
x and presenting white cell count (WCC), After allowing for these features,
blast karyotype, d 8 marrow blast percentage and remission status at the e
nd of induction therapy were the only remaining significant predictors of o
utcome. Organomegaly, haemoglobin concentration, French-American-British ty
pe, body mass index, presence of central nervous system disease at diagnosi
s, immunophenotype and presence of TEL/AML1 fusion gene (examined in a subs
et of 659 patients) either had no significant effect on outcome or were sig
nificant only in univariate analysis, Among karyotype abnormalities with an
independent influence on prognosis, high hyperdiploidy (> 50 chromosomes)
was shown to be favourable, whereas near haploidy (23-29 chromosomes), pres
ence of the Philadelphia chromosome, t(4;11) and abnormalities affecting th
e short arm of chromosome 9 [abn (9p)] were adverse risk factors. Early res
ponders to therapy, determined by residual marrow infiltration after 8d of
induction therapy, had a good outcome, while the small proportion of patien
ts who did not achieve a complete remission by the end of induction therapy
had a poor outcome. A third block of late intensification was shown to imp
rove event-free survival by 8% at 5 years. The effect of these risk factors
was not significantly different between those randomized to the third inte
nsification block and those not randomized to a third block.